Is GENELUX going out of business?

GENELUX Corp (GNLX) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

GENELUX Corp (GNLX) scores 16 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: FCF margin: -329575.00%

Five questions, kept separate

Survival - Fragile

7-10 mo of estimated runway from 2026-06-30, based on $18.7M of cash and short-term investments against $26.4M of annual burn. A disclosed filing event caps this reading; Event Risk carries the detail.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Balanced

15.9% net-cash backing support a balanced pre-commercial Valuation assessment.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. It appears across 3 scanned filings. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• FCF margin: -329575.00%
• Debt / Equity: -1.01x (Net Cash)
• Filing event risk: Going-Concern Warning (-8 pts)
• Revenue CAGR (3Y): -91.03%
• Shares dilution YoY: 22.59% (YoY)
• Return on Assets: -122.67%
• Cash Runway (years): 0.71y
• Price / Sales: 14308.8x (see Valuation)
• Price / Earnings: Unprofitable (see Valuation)

Read from filings through 2026-08-13.

Price as of 2026-09-07.